Evaluate the effectiveness and safety of Bifidobacterium longum subsp. infantis BI45 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period
Willing to self-administer probiotic or placebo once a day during the intervention period
Good eyesight, can read and write, can wear glasses
Have good hearing and be able to hear and understand all instructions during the intervention
Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)
Parallel
Probiotic
Dietary supplementDietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
Placebo
Dietary supplementDietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
Change in the concentration of antimicrobial peptides (LL-37 and calprotectin) in feces before and after intervention
Detected by Enzyme-Linked Immunosorbent Assay (ELISA).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
